• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Denhoy Raj bought $49,972 worth of shares (2,250 units at $22.21), increasing direct ownership by 38% to 8,112 units (SEC Form 4)

    11/20/23 8:00:42 AM ET
    $ESTA
    Industrial Specialties
    Health Care
    Get the next $ESTA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Denhoy Raj

    (Last) (First) (Middle)
    C/O MOTIVA USA LLC
    16192 COASTAL HIGHWAY

    (Street)
    LEWES DE 19958

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ESTABLISHMENT LABS HOLDINGS INC. [ ESTA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    11/17/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Shares 11/17/2023 P 2,250 A $22.21 8,112 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    /s/ Rajbir S. Denhoy 11/20/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ESTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ESTA

    DatePrice TargetRatingAnalyst
    8/20/2025$60.00Buy
    Canaccord Genuity
    5/16/2025$62.00Buy
    BTIG Research
    5/14/2025$48.00Hold → Buy
    Needham
    4/14/2025Hold
    Needham
    5/22/2024$60.00Buy → Neutral
    Citigroup
    8/31/2023$75.00Overweight
    JP Morgan
    6/29/2023$79.00Buy
    Citigroup
    10/14/2022$90.00Overweight
    Stephens
    More analyst ratings

    $ESTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Establishment Labs with a new price target

    Canaccord Genuity initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $60.00

    8/20/25 8:52:36 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    BTIG Research initiated coverage on Establishment Labs with a new price target

    BTIG Research initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $62.00

    5/16/25 8:05:11 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs upgraded by Needham with a new price target

    Needham upgraded Establishment Labs from Hold to Buy and set a new price target of $48.00

    5/14/25 8:49:26 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    See footnote 3 Jw Asset Management, Llc sold $6,636,886 worth of shares (90,533 units at $73.31) (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    5/28/26 8:49:34 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    Director Schutter Edward J was granted 2,354 shares, increasing direct ownership by 1% to 177,736 units (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    5/26/26 4:06:56 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    Director Slotkin Bryan was granted 2,354 shares, increasing direct ownership by 8% to 32,610 units (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    5/26/26 4:07:20 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for It

    Issued on behalf of Conexeu Sciences Inc. With Galderma now presenting clinical data on treating medication-driven facial volume loss, the GLP-1 aesthetics category has gone mainstream — and Conexeu Sciences Inc. (NASDAQ:CNXU) is positioning its regenerative CXU™ platform to compete for it. NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Biotech Insider — In emerging medical markets, the most telling signal is not the small company making the bold claim — it is the giant quietly proving the claim is real. That is exactly what has happened in aesthetics. Galderma, the pure-play dermatology leader behind Sculptra and Restylane, has been presenting interim clinical data demonstrating that i

    6/25/26 9:04:00 AM ET
    $INMD
    $ESTA
    $ABBV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Industrial Specialties
    Biotechnology: Pharmaceutical Preparations

    Establishment Labs® Added to Membership of U.S. Small-Cap Russell 2000® Index

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, will be added as a member of the US small-cap Russell 2000® Index, effective when the US market opens on June 29th as part of the 2026 Russell indexes reconstitution. Membership in the Russell 2000® Index, which remains in place for half a year beginning 2026, is based on membership in the broad-market Russell 3000® Index. The stock was also automatically added to the appropriate growth and value indexes. Russell indexes are widely used by investment managers and institutional investors for index fund

    6/25/26 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower

    Issued on behalf of Conexeu Sciences Inc.A clutch of new directors with Fortune 500 finance, M&A, and aesthetics pedigrees signals that the newly public tissue-regeneration company is building for commercialization — in one of medicine's most consequential frontiers.RENO, Nev., June 16, 2026 /CNW/ -- American News Group News Commentary — There is a well-worn pattern in the life sciences: a company spends years on the science, goes public, and then — in the critical window right after listing — races to assemble the kind of leadership bench that can turn a promising platform into a real business. The names a young company recruits in that window say a great deal about its ambitions. On June 1

    6/16/26 8:15:00 AM ET
    $ABBV
    $ESTA
    $SNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Medical/Dental Instruments

    $ESTA
    Leadership Updates

    Live Leadership Updates

    View All

    After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

    Conexeu Sciences just 3D-bioprinted a new tissue matrix to one of the most respected regenerative medicine institutes in the world. For investors watching how breast reconstruction — and the wider field of tissue regeneration — evolves, the next 18 months matter. NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary — For more than fifty years, breast reconstruction has mostly meant one thing: replacement. A silicone shell, filled with gel, designed to restore shape and volume, none of them designed to regenerate the breast's own living tissue. That gap has consequences. Roughly two-thirds of the more than 100,000 women in the United States who undergo a mastectomy ea

    5/27/26 9:00:00 AM ET
    $ESTA
    $INMD
    $PCRX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Pharmaceutical Preparations

    Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer

    WEST JORDAN, Utah, May 18, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Raj Denhoy to the role of Chief Financial Officer (CFO) effective today. "Route 92 Medical has built a strong position in neurovascular intervention," said Raj Denhoy, CFO at Route 92 Medical. "The company's innovative technologies, the talented team, and, most importantly, the dedication to the mission of improving patient outcomes, set it apart. I could not be more excited to join the company and look forward to contributing to its continued success."

    5/18/26 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Announces Leadership Transition to Support Next Phase of Growth

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced a strategic leadership transition of Raj Denhoy, current Chief Financial Officer to Senior Vice President, Global Strategy, and the appointment of Cassandra "Sandra" Harris to Senior Vice President and Chief Financial Officer, effective March 9, 2026. "Over the past few years, we have been focused on driving efficient execution and scalability. With the company well positioned for its next chapter of growth, we are creating additional leadership capacity to maintain operational momentum

    2/24/26 8:00:00 AM ET
    $ESTA
    $GCO
    Industrial Specialties
    Health Care
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ESTA
    Financials

    Live finance-specific insights

    View All

    Establishment Labs Reports First Quarter 2026 Financial Results

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2026. First Quarter Highlights and Outlook (Unaudited) Revenue of $59.9 million, up 44.7% from Q1 2025, with guidance raised to $266.5 million to $268.5 million $19.6 million of Motiva sales in the United States, up 13.3% from Q4 2025 Minimally invasive revenue of $9.1 million for the quarter Gross margin of 70.7% compared to 67.2% in the year-ago period Loss from operations was $6.5 million compared to a loss of $16.

    5/6/26 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs® to Announce First Quarter 2026 Financial Results on May 6

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2026, before the market opens on Wednesday, May 6, 2026, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, Dial: 877-407-8037 (US & Canada) +1 201-689-8037 (international). The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establishmentlabs.com. About Establishment Labs Est

    4/23/26 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided 2026 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $64.6 million, an increase of 45.2% from the year-ago period. 2025 revenue of $211.1 million, an increase of 27.2% over 2024. Motiva U.S. revenue in the fourth quarter of $17.3 million, and full year U.S. revenue of $45.6 million. Fourth quarter net loss from operations of $3.9 million, a 79% reduction compa

    2/24/26 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lewin Nicholas Sheridan bought $98,410 worth of shares (2,600 units at $37.85) (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    8/14/25 10:58:27 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Director Lewin Nicholas Sheridan bought $78,880 worth of shares (2,300 units at $34.30) (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    8/13/25 11:02:28 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Amendment: Chief Executive Officer Caldini Filippo bought $100,320 worth of shares (2,850 units at $35.20), increasing direct ownership by 9% to 35,245 units (SEC Form 4)

    4/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    8/11/25 4:02:37 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    SEC Filings

    View All

    Establishment Labs Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

    5/22/26 4:29:55 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Establishment Labs Holdings Inc.

    SCHEDULE 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    5/15/26 2:56:56 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Establishment Labs Holdings Inc.

    10-Q - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

    5/8/26 4:08:27 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Establishment Labs Holdings Inc.

    SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    11/12/24 12:54:20 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Establishment Labs Holdings Inc.

    SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    11/12/24 9:03:38 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Establishment Labs Holdings Inc. (Amendment)

    SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    2/14/24 4:51:40 PM ET
    $ESTA
    Industrial Specialties
    Health Care